Ilya Kister, Ryan Curtin, Amanda L Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E Bacon, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie, Sean Selva, Marie I Samanovic, Mark J Mulligan, Yury Patskovsky, Jessica Priest, Mark Cabatingan, Ryan C Winger, Michelle Krogsgaard, Gregg J Silverman
OBJECTIVES: (1) To plot the trajectory of humoral and cellular immune responses to the primary (two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple sclerosis (MS) patients up to 2 years post-vaccination; (2) to identify predictors of immune responses to vaccination; and (3) to assess the impact of intercurrent COVID-19 infections on SARS CoV-2-specific immunity. METHODS: Sixty ocrelizumab-treated MS patients were enrolled from NYU (New York) and University of Colorado (Anschutz) MS Centers...
May 7, 2024: Annals of Clinical and Translational Neurology